Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,924 shares of the biopharmaceutical company's stock after selling 6,651 shares during the quarter. Gotham Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $2,571,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in ALNY. Capital World Investors grew its stake in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after buying an additional 98,303 shares during the period. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after buying an additional 1,245,195 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 2.3%

Shares of NASDAQ:ALNY traded up $6.55 during midday trading on Monday, reaching $291.86. The company's stock had a trading volume of 929,466 shares, compared to its average volume of 911,976. The business has a 50 day moving average price of $253.73 and a 200 day moving average price of $253.49. The firm has a market cap of $38.06 billion, a price-to-earnings ratio of -134.50 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ALNY. UBS Group raised their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Bank of America raised their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.